- Page 1 and 2:
NHS National Institute for Health a
- Page 3 and 4:
Contents Improving Outcomes for Peo
- Page 5 and 6:
Patient information ...............
- Page 7 and 8:
Resource implications .............
- Page 9 and 10:
Foreword Improving Outcomes for Peo
- Page 11 and 12:
- referral - review of patient care
- Page 13 and 14:
early detection have been published
- Page 15 and 16:
The epidemiology of skin cancers an
- Page 17 and 18:
The incidence of MM increases with
- Page 19 and 20:
Figure 5. Mortality from MM, Englan
- Page 21 and 22:
Figure 8. Incidence of NMSC, Englan
- Page 23 and 24:
Risk factors for skin cancer As ski
- Page 25 and 26:
Figure 12. Rates of episodes of inp
- Page 27 and 28:
Two-week wait data Urgent skin canc
- Page 29 and 30:
• Improving the experience of car
- Page 31 and 32:
12. National Institute for Clinical
- Page 33 and 34:
Patient-centred care Improving Outc
- Page 35 and 36:
This document and the NICE Referral
- Page 37 and 38:
A checklist may be used by healthca
- Page 39 and 40:
Quality assurance Surveys of patien
- Page 41 and 42:
One cross-sectional study found tha
- Page 43 and 44:
One RCT conducted with patients wit
- Page 45 and 46:
• Every skin cancer MDT having ac
- Page 47 and 48:
to estimate a separate cost for ser
- Page 49 and 50:
department or they may be referred
- Page 51 and 52:
The 2-week waiting time standard an
- Page 53 and 54:
The local hospital skin cancer mult
- Page 55 and 56:
A function of the LSMDT is to audit
- Page 57 and 58:
• lymphoedema therapists • phar
- Page 59 and 60:
SSMDT meetings should be at least f
- Page 61 and 62:
As set out in the section on ‘Arr
- Page 63 and 64:
• Palliative care specialists. Si
- Page 65 and 66:
Videoconferencing and teleconferenc
- Page 67 and 68:
A basic knowledge of skin cancer hi
- Page 69 and 70:
B. Anticipated benefits At present,
- Page 71 and 72:
One systematic review (of the abili
- Page 73 and 74:
One retrospective study compared pa
- Page 75 and 76:
• Critical incidents where treatm
- Page 77 and 78:
Network-wide protocols It is not po
- Page 79 and 80:
Initial investigation, diagnosis, s
- Page 81 and 82:
Figure 14. Skin lesion - patient pa
- Page 83 and 84:
curettage (as recommended in BAD gu
- Page 85 and 86:
Diclofenac 3% gel (Solaraze) is lic
- Page 87 and 88:
Histopathology services for skin ca
- Page 89 and 90:
Patients with anogenital Bowen’s
- Page 91 and 92:
B. Anticipated benefits Better-qual
- Page 93 and 94:
One RCT compared teledermatology wi
- Page 95 and 96:
One systematic review based upon 12
- Page 97 and 98:
Expert review evidence suggests tha
- Page 99 and 100:
Immunotherapy An RCT comparing allo
- Page 101 and 102:
• Adherence to treatment protocol
- Page 103 and 104:
F. Research priorities • Given th
- Page 105 and 106:
For patients with low-risk BCC or S
- Page 107 and 108:
Follow-up for patients after treatm
- Page 109 and 110:
C. Evidence Evidence exists that ea
- Page 111 and 112:
One observational study found that
- Page 113 and 114:
The written and photographic inform
- Page 115 and 116:
Genetic predisposition to MM may al
- Page 117 and 118:
patients with cutaneous lymphoma sh
- Page 119 and 120:
A. Recommendations Generic recommen
- Page 121 and 122: Cutaneous lymphoma All patients sho
- Page 123 and 124: Children and young people with skin
- Page 125 and 126: Gorlin’s syndrome Two expert revi
- Page 127 and 128: Process • Audit of adherence to p
- Page 129 and 130: • Cutaneous lymphoma is so rare t
- Page 131 and 132: Dermal and subcutaneous tumours Aty
- Page 133 and 134: c) The guidance will also refer to
- Page 135 and 136: 4.2.2 Healthcare settings and servi
- Page 137 and 138: Referral from the Department of Hea
- Page 139 and 140: Table A1. Summary of service option
- Page 141 and 142: For those cancer networks with part
- Page 143 and 144: Appendix 4 How this guidance manual
- Page 145 and 146: Appendix 5 People and organisations
- Page 147 and 148: Professor Julia Newton-Bishop Mr Ba
- Page 149 and 150: • Bristol South and West PCT •
- Page 151 and 152: • Healthcare Commission • Help
- Page 153 and 154: • Royal College of Surgeons of En
- Page 155 and 156: Appendix 5.3 Researchers carrying o
- Page 157 and 158: Appendix 5.4 Expert advisers to the
- Page 159 and 160: Appendix 5.5 Report* commissioned t
- Page 161 and 162: Appendix 6 Glossary of terms Improv
- Page 163 and 164: Chemoprophylaxis The use of a drug
- Page 165 and 166: Electrodesiccation A surgical metho
- Page 167 and 168: Immunotherapy Treatment by stimulat
- Page 169 and 170: Morbidity A diseased condition or s
- Page 171: Prognosis A prediction of the likel
- Page 175 and 176: KS LHB LSMDT MCC MDT MM MRI NCC-C N